European Growth Stocks Insiders Are Eager To Own
I'm LongbridgeAI, I can summarize articles.European markets are rallying, with the STOXX Europe 600 Index up over 3% following a U.S.-Iran ceasefire. Investor sentiment is cautiously optimistic, particularly towards growth companies with high insider ownership, indicating confidence from management. Notable companies include KebNi, Induct, and Verve Group, all showing significant earnings growth and insider ownership. Newron Pharmaceuticals and Semperit Holding, despite challenges, also show potential for growth. The article emphasizes the importance of insider ownership in assessing company prospects and highlights a list of 216 fast-growing European companies with high insider ownership.
As European markets rally following a U.S.-Iran ceasefire, with the STOXX Europe 600 Index climbing over 3%, investor sentiment appears to be cautiously optimistic despite looming economic uncertainties. In such an environment, growth companies with high insider ownership can be particularly appealing, as they often indicate confidence from those closest to the business and potential alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 13.7% | 34.7% |
| KebNi (OM:KEBNI B) | 35% | 72.8% |
| Induct (OB:INDCT) | 10.5% | 98.6% |
| Hacksaw (OM:HACK) | 13.2% | 25.3% |
| Elliptic Laboratories (OB:ELABS) | 19.8% | 124.9% |
| CTT Systems (OM:CTT) | 17.4% | 42.7% |
| Clavister Holding AB (publ.) (OM:CLAV) | 18% | 116.2% |
| Circus (XTRA:CA1) | 21.9% | 88.1% |
| Bonesupport Holding (OM:BONEX) | 10.2% | 33.7% |
| Bergen Carbon Solutions (OB:BCS) | 10.2% | 55.5% |
Click here to see the full list of 216 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Let's uncover some gems from our specialized screener.
Newron Pharmaceuticals (SWX:NWRN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on discovering and developing novel therapies for central and peripheral nervous system diseases in Italy and the United States, with a market cap of CHF340.38 million.
Operations: The company's revenue is primarily derived from its Research and Development of Pharmaceutical Drugs segment, amounting to €19.13 million.
Insider Ownership: 10.1%
Newron Pharmaceuticals, despite its high insider ownership, faces challenges with recent financials showing a significant revenue drop to €19.13 million and a net loss of €13.24 million for 2025. The forecasted revenue growth rate of 36.4% annually surpasses the Swiss market average, indicating potential for expansion. However, concerns arise from an auditor's going concern doubts and negative shareholders' equity. Notably, Newron is advancing evenamide in Phase III trials as a promising treatment for schizophrenia.
- Dive into the specifics of Newron Pharmaceuticals here with our thorough growth forecast report.
- Our valuation report unveils the possibility Newron Pharmaceuticals' shares may be trading at a discount.
Semperit Holding (WBAG:SEM)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Semperit Aktiengesellschaft Holding is a company that develops, produces, and sells rubber and polymer products across Europe, America, Asia-Pacific, and Africa with a market cap of €306.54 million.
Operations: The company's revenue segments include €391.53 million from Engineered Applications and €271.07 million from Industrial Applications.
Insider Ownership: 10.1%
Semperit Holding, while experiencing a decline in net income to €0.42 million for 2025, is poised for growth with earnings projected to rise significantly at 55.9% annually, outpacing the Austrian market. The company trades below its estimated fair value and analyst price targets suggest potential upside. Despite no recent insider buying activity, B & C Holding's acquisition proposal underscores confidence in Semperit's future prospects amid prioritization of financial strengthening over dividends.
- Click here to discover the nuances of Semperit Holding with our detailed analytical future growth report.
- The analysis detailed in our Semperit Holding valuation report hints at an deflated share price compared to its estimated value.
Verve Group (XTRA:VRV)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Verve Group SE is a digital media company that provides ad-software solutions in North America and Europe, with a market cap of €287.77 million.
Operations: The company's revenue is derived from Demand Side Platforms (DSP) generating €157.63 million and Supply Side Platforms (SSP) contributing €455.13 million.
Insider Ownership: 21.4%
Verve Group SE is experiencing significant insider buying, indicating strong internal confidence. The company's recent expansion into AI chat environments enhances its advertising platform, positioning it as a leader in high-fidelity intent data utilization. Despite volatile share prices and low profit margins of 0.1%, Verve's earnings are forecast to grow significantly at 36.4% annually, surpassing the German market average. Trading well below fair value estimates, Verve presents potential growth opportunities amidst financial challenges like insufficient interest coverage by earnings.
- Take a closer look at Verve Group's potential here in our earnings growth report.
- The valuation report we've compiled suggests that Verve Group's current price could be quite moderate.
Summing It All Up
- Access the full spectrum of 216 Fast Growing European Companies With High Insider Ownership by clicking on this link.
- Want To Explore Some Alternatives? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Try a Demo Portfolio for Free
